Recovery after l-DOPA treatment in peginterferon and ribavirin induced parkinsonism

European Journal of Internal Medicine

Volumn 19, Issue 5, 2008, Pages 370-371

  Bersano, A ^a   Aghemo, A ^a   Rumi, M G ^a   Ballabio, E ^a   Candelise, L ^a   Colombo, M ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

HCV; Levodopa; Parkinsonism; PegInterferon; Side effects

Indexed keywords

ATENOLOL; BENSERAZIDE; LEVODOPA; PEGINTERFERON ALPHA2A; PRIMIDONE; RIBAVIRIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; MALE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; RELAPSE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIPARKINSON AGENTS; ANTIVIRAL AGENTS; BENSERAZIDE; DRUG THERAPY, COMBINATION; HUMANS; INTERFERON ALFA-2A; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 44849090388     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.10.003     Document Type: Article

References (6)

1. Alberti A., Chemello L., and Benvegnu L. Natural history of hepatitis C. J Hepatol 31 1 (1999) 17-24
2. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
3. Atasoy N., Ustundag Y., Konuk N., and Atik L. Acute dystonia during pegylated interferon alpha therapy in a case with chronic hepatitis B infection. Clin Neuropharmacol 27 (2004) 105-107
4. Meyers C.A., Scheibel R.S., and Forman A.D. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 41 (1991) 672-676
5. Gelb D.J., Oliver E., and Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 56 (1999) 33-39
6. Shuto H., Kataoka Y., Horikawa T., Fujihara N., and Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 747 (1997) 348-351